.

Deeper Knowledge, Faster

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Medtronic
Deloitte
Johnson and Johnson
Express Scripts
McKinsey
UBS
Healthtrust
Chinese Patent Office
Queensland Health
Novartis

Generated: September 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 040156

« Back to Dashboard
NDA 040156 describes HYDROXYZINE PAMOATE, which is a drug marketed by Watson Labs, Heritage Pharma, Sandoz, Superpharm, Par Pharm, Impax Labs Inc, Ivax Sub Teva Pharms, Barr, Vangard, and Duramed Pharms Barr, and is included in thirty-four NDAs. It is available from thirty-five suppliers. Additional details are available on the HYDROXYZINE PAMOATE profile page.

The generic ingredient in HYDROXYZINE PAMOATE is hydroxyzine pamoate. There are nineteen drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the hydroxyzine pamoate profile page.

Summary for NDA: 040156

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Antiemetics
Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 040156

Mechanism of ActionHistamine Receptor Antagonists

Suppliers and Packaging for NDA: 040156

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HYDROXYZINE PAMOATE
hydroxyzine pamoate
 CAPSULE;ORAL 040156 ANDA Impax Generics 0115-1670 0115-1670-01 100 CAPSULE in 1 BOTTLE, PLASTIC (0115-1670-01)
HYDROXYZINE PAMOATE
hydroxyzine pamoate
 CAPSULE;ORAL 040156 ANDA Impax Generics 0115-1670 0115-1670-02 500 CAPSULE in 1 BOTTLE, PLASTIC (0115-1670-02)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 25MG HCL
Approval Date:Jul 15, 1996TE:ABRLD:No

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 50MG HCL
Approval Date:Jul 15, 1996TE:ABRLD:No


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Citi
Deloitte
UBS
Cerilliant
Merck
Queensland Health
Chinese Patent Office
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions
Related Products from thinkBiotech
Links

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot